Medpace (MEDP) · wyniki II kw. 2026 i wycena

Przy wzroście 20,0% rocznie (3-letni wzrost przychodów) wartość godziwa z modelu to $1221.67 na akcję — kurs jest o 47% poniżej niej. Obecna cena zakłada wzrost o 11,2% rocznie.

1. Główny temat

   Year-to-date net income rose to $245.2 million from $204.9 million, helped by a lower tax rate and higher interest income.

   Cytat ze źródła

   “Year to date net income was $245.2 million compared to $204.9 million in the comparable prior year period. Net income growth above EBITDA growth was primarily driven by a lower effective tax rate and higher interest income compared to the prior year period. Which represents a 19.7% increase.”

2. Prognoza

   About $1.96 billion in current backlog is expected to turn into revenue over the next year.

   Cytat ze źródła

   “We project that approximately $1.96 billion of backlog will convert to revenue in the next 12 months.”

3. Prognoza

   Full-year 2026 net income is forecast at $494 million to $514 million, assuming an effective tax rate of 19% to 19.5%.

   Cytat ze źródła

   “We forecast 2026 net income in the range of $494 million to $514 million This guidance assumes a full year 2026 effective tax rate of 19% to 19.5%...”

4. Liczba

   Revenue for the six months ended June 30, 2026, was $1.41 billion, which increased 21.7% compared to the previous period.

   Cytat ze źródła

   “Revenue for the 6 months ended June 30, 2026 was $1.41 billion, and increased 21.7%.”

Script and answers carried a similar tone, so the script's message held up under questioning.

Zdania, które wpłynęły na ton

“RFPs were up sequentially and year over year, generating high quality opportunities.”

“And I think were a possible you know, influence our very strong win rate in Q1.”

“And we do expect high single digit you know, growth in employees, you know, this year.”